The Medical University of Innsbruck has approximately 1,400 (full-time equivalent) employees and around 3,000 students and, together with the University of Innsbruck, is the largest educational and research institution in western Austria and the regional university for Tyrol, Vorarlberg, South Tyrol and Liechtenstein. The following courses are offered at Medical University of Innsbruck: Medicine and Dentistry as the basis of an academic medical degree and a PhD degree (PhD) as the postgraduate aspect of scientific work. The bachelor's degree in Molecular Medicine is new in the curriculum since autumn 2011. There is the possibility to continue with a master degree in Molecular Medicine.
The Medical University of Innsbruck is involved in numerous international educational and research programmes and networks. The research focuses on the areas Oncology, Neuroscience, Genetics, Epigenetics and Genomics as well as Infectious Diseases, Immunology & Organ and Tissue Repair. In addition to scientific research, Medical University of Innsbruck is also nationally and internationally very successful in the highly competitive field of research funding.
The clinics are located at the Provincial Hospital (‘Tiroler Landeskrankenhaus’) which is simultaneously Medical University`s of Innsbruck hospital with more than 4,700 employees conducting 85,000 admissions per year.
The Medical University`s Clinic for Internal Medicine III – Cardiology & Angiology became dedicated project partner for Lab-2Go.
Pre-clinical evaluation of the handheld Point-of-Care diagnostic device measuring cardiac Troponin I in everyday clinical conditions to test suitability for routine use of the device and evaluation of the cardiac Troponin I assay compared to high-sensitivity cardiac troponin T.
Associate Professor Johannes Mair
Senior Staff Member at the Department of Cardiology, Associate Professor of Internal Medicine and Associate Professor of Clinical Chemistry and Laboratory Medicine at Innsbruck Medical University. Founding member of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), Committee on the Standardization of Markers of Cardiac Damage (C-SMCD) and the Study Group on Cardiac Biomarkers of the European Society of Cardiology Association of Acute Cardiac Care.
Christina Mayerl (Study monitor)
Christina is a Clinical Research Associate at the Department of Cardiology. She focused in her research in the molecular and cellular basis of fibrotic diseases and especially atherosclerosis and obtained a degree in Medical Sciences (PhD). Christina has longstanding experience in managing in pre-clinical and clinical trials.